Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01)

2026-06-29

PRE

Junpei Yamaguchi *

Hideki Takami

Yukihiro Yokoyama

Tsutomu Fujii

Suguru Yamada

Hiroki Kawashima

Takuya Ishikawa

Osamu Maeda

Hiroshi Ogawa

Tomoki Ebata

DOI：10.1002/jhbp.70150

Original

Original request for help

Save

Abstract

En 中文

Initial results of NUPAT-01 suggest the feasibility of multidrug neoadjuvant chemotherapy for borderline-resectable pancreatic cancer and favorable survival of patients, and we report on the long-term results of this study.

Keywords:

chemotherapy

pancreatic cancer

surgery

Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01)

Abstract

Journal

Organization

Cited Papers

Citing Papers